Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.01.2016 | original article | Ausgabe 1-2/2016

Wiener klinische Wochenschrift 1-2/2016

Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease

Wiener klinische Wochenschrift > Ausgabe 1-2/2016
MD Erdem Akbal, MD Erdem Koçak, MD Assist. Prof. Ömer Akyürek, MD Seyfettin Köklü, MD Hikmetullah Batgi, MD Mehmet Şenes


Background and aims

Liver fatty acid-binding protein (L-FABP) is a small cytoplasmic protein. The aim of the current study was to investigate L-FABP levels and to determine their diagnostic value for non-alcoholic fatty liver disease (NAFLD).


We enrolled in this study 24 consecutive patients with NAFLD who were diagnosed with elevated transaminases and with steatosis by ultrasonograph. The control group consisted of 22 healthy control subjects matched for age and gender. Serum levels of L-FABP were determined by enzyme-linked immunosorbent assay.


L-FABP levels in NAFLD patients were higher than in the control group (levels were 41,976 ± 18,998 and 17048 ± 5021 pg/mL, respectively). A strong correlation was found between serum L-FABP concentrations and aspartate aminotransferase, alanine aminotransferase, body mass index, glucose and γ-glutamyltransferase levels. A level of 284,000 pg/mL L-FABP had 73 % sensitivity and 100 % specificity. Positive and negative predictive values for L-FABP were 100  and 79%, respectively.


Serum L-FABP can be considered as a new diagnostic marker for detecting non-alcoholic fatty liver disease.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2016

Wiener klinische Wochenschrift 1-2/2016 Zur Ausgabe



MUW researcher of the month

MUW researcher of the month Januar 2016